Boehringer Ingelheim's Lung Cancer Drug Hernexeos Gains FDA Approval
TL;DR Summary
The US FDA has approved Boehringer Ingelheim's drug Hernexeos for treating advanced non-squamous non-small cell lung cancer in patients who have previously received treatment, based on a study showing significant tumor reduction, with an accompanying diagnostic device approval for patient identification.
- US FDA approves Boehringer Ingelheim's lung cancer treatment Reuters
- Top German Pharma Boehringer Wins US Approval for Cancer Drug Bloomberg.com
- FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations OncLive
- Amol Akhade: Zongertinib - A New Targeted Therapy Option for a Rare Molecular Subset of Lung Cancer Oncodaily
- Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med Hernexeos Fierce Pharma
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
82%
224 → 41 words
Want the full story? Read the original article
Read on Reuters